Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transparency task force to mull announcements of NDAs

This article was originally published in The Tan Sheet

Executive Summary

FDA will ask whether the public should be informed when sponsors file applications for drugs and other products, at a second public Transparency Task Force meeting Nov. 3 in Washington to discuss the communication issues. Topics include "early communication about emerging safety issues concerning FDA-regulated products," disclosure of information about abandoned or withdrawn product applications and communication of agency decisions about pending product applications. Attendees must register by 5 p.m. on Oct. 27, and comments must be submitted electronically by Nov. 6 (1"The Tan Sheet" Sept. 14, 2009)
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS103399

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel